STOCK TITAN

Nanobiotix (NASDAQ: NBTX) updates share count and votes

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Nanobiotix S.A. (NBTX) reported its share capital and voting rights position as of July 31, 2026, in line with articles L.233-8 II of the French Commercial Code and article 223-16 of the General Regulation of the French Financial Markets Authority. The company had 50,833,462 shares outstanding. Total theoretical voting rights were 54,534,179, while total exercisable voting rights at shareholder meetings were 54,512,061, reflecting the exclusion of shares with suspended voting rights such as treasury shares. Nanobiotix remains listed on Euronext Paris and the Nasdaq Global Select Market.

Positive

  • None.

Negative

  • None.
Shares outstanding 50,833,462 shares As of July 31, 2026
Total voting rights, theoretical 54,534,179 voting rights Used as basis for threshold crossings, as of July 31, 2026
Total voting rights, exercisable 54,512,061 voting rights Excludes shares with suspended voting rights, as of July 31, 2026
Market listing Euronext Paris / Nasdaq Global Select Market Current trading venues for Nanobiotix shares
Date of reference July 31, 2026 Reference date for share capital and voting rights table
theoretical voting rights financial
"The total number of theoretical (or “gross”) voting rights is used"
Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.
exercisable voting rights financial
"The total number of exercisable at a shareholders’ meeting (or “net”)"
Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.
French Commercial Code regulatory
"In accordance with articles L.233-8 II of the French Commercial Code"
The French Commercial Code is the national rulebook that sets the legal framework for business activity in France, covering company formation and governance, commercial contracts, trade practices, bankruptcy procedures and the role of commercial courts. For investors, it matters because these rules determine how companies are structured, how contracts and disputes are handled, and how creditor and shareholder rights are protected — like an operating manual that shapes business risk and legal recourse.
Autorité des Marchés Financiers regulatory
"of the French Financial Markets Authority (Autorité des Marchés Financiers)"
Autorité des marchés financiers is the French-language name for an independent government agency that supervises and enforces rules for securities markets, financial firms, and investor protection. It matters to investors because it requires companies to publish accurate information, polices fraud and insider trading, and can suspend trading or impose penalties—acting like a referee and safety inspector to help markets stay fair and reliable and to give investors confidence and recourse.

FAQ

How many shares of Nanobiotix S.A. (NBTX) were outstanding on July 31, 2026?

On July 31, 2026, Nanobiotix S.A. had 50,833,462 shares outstanding. This figure represents the total number of issued shares that form the basis for the company’s reported voting rights and share capital disclosure.

What were Nanobiotix (NBTX)'s total theoretical voting rights as of July 31, 2026?

As of July 31, 2026, Nanobiotix reported 54,534,179 theoretical voting rights. This “gross” number includes all shares to which voting rights are attached, even those where voting rights are suspended, and is used for calculating threshold crossings under AMF rules.

What were the exercisable voting rights for Nanobiotix (NBTX) on July 31, 2026?

Nanobiotix reported 54,512,061 exercisable voting rights as of July 31, 2026. This “net” figure excludes shares with suspended voting rights, such as treasury shares, and represents the voting rights that can be exercised at a shareholders’ meeting.

Why does Nanobiotix (NBTX) disclose theoretical and exercisable voting rights?

Nanobiotix discloses both theoretical and exercisable voting rights to comply with French regulations, including article L.233-8 II of the French Commercial Code and article 223-16 of the AMF General Regulation, and to ensure the market is properly informed about its share capital structure.

On which markets are Nanobiotix (NBTX) shares listed?

Nanobiotix shares are listed on Euronext Paris and on the Nasdaq Global Select Market in New York City. The company’s ISIN code is FR0011341205, and its Nasdaq ticker symbol is NBTX.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 


On August 25, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated August 25, 2026


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Nanobiotix S.A.    
  (Registrant)
   
  
Date: August 25, 2026     /s/ Bart Van Rhijn    
  Bart Van Rhijn
  Chief Financial Officer
  

EXHIBIT 99.1

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date




Number of Shares
Outstanding




Total number of voting rights
Total voting rights,
theoretical
1
Total voting rights,
exercisable2
July 31, 202650,833,46254,534,17954,512,061

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix 
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
+1 (713) 609-3150

Ricky Bhajun
Director, Investor Relations (EU)

investors@nanobiotix.com
 
Media Relations 

France – HARDY
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr

Global – uncapped
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com
 


__________________
1
The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Attachment

  • 2026-08-25 -- NBTX -- Voting Rights & Shares Capital -- FINAL (https://ml.globenewswire.com/Resource/Download/a75fc54f-7266-4d49-8fa7-8f1990b8cbbe)

Filing Exhibits & Attachments

1 document